SCPS (Scopus BioPharma) EV-to-EBIT: -0.00 (As of Jul. 13, 2026)


What is Scopus BioPharma EV-to-EBIT?

Scopus BioPharma SCPS EV-to-EBIT is -0.00 as of Jul. 13, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Scopus BioPharma's Enterprise Value is $0.01 Mil. Scopus BioPharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-9.34 Mil. Therefore, Scopus BioPharma's EV-to-EBIT for today is -0.00.

The historical rank and industry rank for Scopus BioPharma's EV-to-EBIT or its related term are showing as below:

SCPS's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 14.29
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Scopus BioPharma's Enterprise Value for the quarter that ended in Jun. 2023 was $0.86 Mil. Scopus BioPharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-9.34 Mil. Scopus BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -1,089.63%.

Scopus BioPharma  (OTCPK:SCPS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Scopus BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-9.344/0.857536
=-1,089.63 %

Scopus BioPharma's Enterprise Value for the quarter that ended in Jun. 2023 was $0.86 Mil.
Scopus BioPharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma EV-to-EBIT Related Terms

Scopus BioPharma EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma EV-to-EBIT Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial 0.00 0.00 -21.35 -1.01 -0.12

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.29 -0.12 -0.02 -0.09

SCPS vs AMPE, DRMA, SPRC: EV-to-EBIT Comparison

For the Biotechnology subindustry, Scopus BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's EV-to-EBIT falls into.


Scopus BioPharma EV-to-EBIT Calculation

Scopus BioPharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.013/-9.344
=-0.00

Scopus BioPharma's current Enterprise Value is $0.01 Mil.
Scopus BioPharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of -0.00 mean?
Scopus BioPharma (SCPS) has a EV-to-EBIT of -0.00 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's EV-to-EBIT too high?
Scopus BioPharma's current EV-to-EBIT is -0.00.
How does Scopus BioPharma's EV-to-EBIT compare to AMPE and DRMA?
Scopus BioPharma's EV-to-EBIT of -0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 14.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.29, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scopus BioPharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scopus BioPharma's current EV-to-EBIT is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current EV-to-EBIT of -0.00. The current EV-to-EBIT is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current EV-to-EBIT is -0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.